Telix Appoints Gabrielle Wermenbol as Chief Financial Officer, EMEA
19 July 2021 – Corporate Spotlight | Gabrielle Wermenbol joins Telix as Chief Financial Officer, Europe, Middle East & Africa (EMEA)
Telix is delighted to announce the appointment of Gabrielle Wermenbol as Chief Financial Officer, Europe, Middle East and Africa (EMEA).
Gabrielle brings with her over 20 years’ experience in life sciences, pharmaceutical and consumer goods businesses, and has held executive positions with companies including Johnson & Johnson, medical devices company, Terumo Europe, and Pfizer’s animal health spin-off, Zoetis, where she also served as a Board member.
She has a Master’s degree in Applied Economic Sciences from the University of Antwerp, Belgium, along with an MBA from Xavier’s Institute of Management in Orissa, India.
With widespread experience in business transformation and team building, Gabrielle is the ideal fit to lead Telix’s financial operations in EMEA as we prepare for the commercial launch of our lead product Illuccix® for prostate cancer imaging.
On joining Telix, Gabrielle stated, “I am very excited to start my new challenge at Telix and look forward to working with the team to support the company in the transition to commercialisation and revenue generation. Telix is full of potential with a comprehensive late stage portfolio to both diagnose and treat different types of cancer and make a difference in patients’ lives for the better, and I am proud to be part of that journey.”
We welcome Gabrielle to the Telix team, as we work to deliver on our mission to help patients with cancer live longer, better quality lives.
To return to our home page please click here.